PET Tau - Neurodegenerative Disease Imaging
-
- STATUS
- Recruiting
-
- End date
- Dec 20, 2023
-
- participants needed
- 300
-
- sponsor
- University of Pennsylvania
Summary
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
Description
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells, including Alzheimer's disease, Parkinson's disease, Lewy body disease and Frontotemporal degeneration. [18F]T807 (also known as 18F-AV- 1451) is a specialized radioactive PET tracer that sticks to the tau protein in the brain. In this study, researchers will use [18F]T807 to form images of tau binding in the brain. [18F]T807 is an investigational or experimental imaging agent that has not yet been approved by the Food and Drug Administration for use in brain imaging.
In this study, researchers want to find out how accurate and useful [18F]T807 is in imaging patients who have problems with thinking, remembering, speech, and visual activities, and may be diagnosed with different types of neurodegenerative disease. This study will help test how imaging measures may provide information that could be used to determine diagnosis for patients in the future. The results of the PET/CT scan will be compared with other information obtained under related protocols, including brain magnetic resonance imaging (MRI), spinal fluid and cognitive test results.
Details
| Condition | Neurodegenerative Disease |
|---|---|
| Treatment | [18F]T807 (also known as 18F-AV- 1451), [18F]T807 |
| Clinical Study Identifier | NCT03143374 |
| Sponsor | University of Pennsylvania |
| Last Modified on | 20 April 2022 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer